Pharmacy | Home | MIMS Malaysia

Malaysia
Search
Sign In

Pharmacy

Pharmacy

Home News Conferences Special Reports Multimedia

Young, healthy people still at-risk for CVD if LDL-C is high

Pearl Toh, 7 hours ago

Young, healthy individuals at low risk for atherosclerotic cardiovascular disease (ASCVD) events may still face a heightened lifetime risk of death from CV events if they have elevated LDL-C levels of ≥160 mg/dL, reveal the CCLS*.

Brentuximab vedotin + CHP doubles PFS over CHOP in CD30+ peripheral T-cell lymphoma

Roshini Claire Anthony, 12 hours ago

The combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) more than doubled progression-free survival (PFS) as well as improved overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma compared with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to results of the phase III ECHELON-2* trial.

Intensive vs moderate statin therapy ups risk of early discontinuation

12 hours ago

Intensive statin therapy in the secondary prevention of ischaemic stroke or transient ischaemic attack significantly increases the risk of premature discontinuation as compared with a moderate intensity, a study has found.

Direct switch to IND/GLY from SFC improves predose FEV1, FVC in COPD patients

15 hours ago

A direct switch to indacaterol/glycopyrronium (IND/GLY) from salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with up to one exacerbation in the previous year improves predose forced expiratory volume in 1 s (FEV1) and forced vital capacity without presenting new safety signals, a recent study has found.

Maintenance olaparib provides survival advantage in mutated ovarian cancer

Jairia Dela Cruz, 15 hours ago

The use of the PARP inhibitor olaparib in the maintenance setting confers notable gains in progression-free survival in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, according to data from the phase III SOLO1 trial.

Evolocumab confers cardioprotection by lowering lipoprotein(a) levels

20 hours ago

Elevated lipoprotein(a) [Lp(a)] carries an increased risk of cardiovascular (CV) events in patients with established CV disease independent of low-density lipoprotein cholesterol, according to a study. PCSK9 inhibition with evolocumab reduces Lp(a) levels, and the cardioprotective effect is pronounced in patients with higher Lp(a) levels at baseline.

Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective

01 Nov 2018

The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

Optimizing CV outcomes with evolocumab

Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

Luspatercept lowers need for RBC transfusion in MDS

Elaine Soliven, 10 Dec 2018

Treatment with luspatercept, a first-in-class erythroid maturation agent, significantly achieves red blood cell transfusion independence (RBC-TI) in patients with anaemia who had low-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS), according to results of the MEDALIST* trial presented at ASH 2018.

Apixaban trumps standard treatment in preventing cancer-associated VTE recurrence

Pearl Toh, 07 Dec 2018

Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

MURANO solidifies venetoclax-rituximab combo for relapsed/refractory CLL

Roshini Claire Anthony, 07 Dec 2018

Findings from the updated analysis of the phase III MURANO* trial solidify the role of fixed-dose venetoclax plus rituximab in a majority of patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).

Gene therapy promising in severe haemophilia B

Elvira Manzano, 07 Dec 2018

Systemic administration of the gene therapy scAAV2/8-LP1-hFIXco to patients with severe haemophilia B led to stable therapeutic expression of the factor IX gene over 8 years without evidence of late toxicities from treatment, according to a long-term follow-up study.

Apalutamide equally beneficial in Asians with nmCRPC

Elvira Manzano, 05 Dec 2018

Apalutamide, added to standard treatment with androgen deprivation therapy (ADT), provides comparable clinical benefits among Asian vs non-Asian patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a subset analysis of the phase III SPARTAN study.

Elaine Soliven, 05 Dec 2018

Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.

Beta blockers, renin-angiotensin inhibitors may thwart anthracycline-induced cardiotoxicity

Jairia Dela Cruz, 05 Dec 2018

Beta blockers and/or renin-angiotensin inhibitors appear to be useful for preventing cardiotoxicity from anthracycline exposure, according to the results of a systematic review and meta-analysis presented at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!